Floatz logo

Capecitabine

EBV-Positive DLBCL, Nos

Huiqiang HuangSmall moleculePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the EBV-Positive DLBCL, Nos cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Patrick C. Johnson, MD
Phase 2B
DEXAMETHASONE
University of Washington
Phase 2B
Acalabrutinib
Patrick C. Johnson, MD
Phase 2CCC
Pyrotinib
Ruijin Hospital
Phase 2CCC
rc48-adc
Ruijin Hospital
Phase 2CCC

View all 14 →

Same molecule, other indications

Capecitabine is also rated in:

Locally Advanced Rectal CancerDormant
BBB
Indicative ·
75 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →
rectal carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →